| Literature DB >> 35584628 |
Claudia C Faria1, Rita Cascão2, Carlos Custódia2, Eunice Paisana2, Tânia Carvalho2, Pedro Pereira3, Rafael Roque3, José Pimentel3, José Miguéns4, Isidro Cortes-Ciriano5, João T Barata2.
Abstract
Dissemination of cancer cells from primary tumors to the brain occurs in many cancer patients, increasing morbidity and death. There is an unmet medical need to develop translational platforms to evaluate therapeutic responses. Toward this goal, we established a library of 23 patient-derived xenografts (PDXs) of brain metastases (BMs) from eight distinct primary tumors. In vivo tumor formation correlates with patients' poor survival. Mouse subcutaneous xenografts develop spontaneous metastases and intracardiac PDXs increase dissemination to the CNS, both models mimicking the dissemination pattern of the donor patient. We test the FDA-approved drugs buparlisib (pan-PI3K inhibitor) and everolimus (mTOR inhibitor) and show their efficacy in treating our models. Finally, we show by RNA sequencing that human BMs and their matched PDXs have similar transcriptional profiles. Overall, these models of BMs recapitulate the biology of human metastatic disease and can be valuable translational platforms for precision medicine.Entities:
Keywords: PI3K inhibitor; RNA sequencing; brain metastases; mTOR inhibitor; patient-derived cultures; patient-derived xenografts
Mesh:
Substances:
Year: 2022 PMID: 35584628 PMCID: PMC9133464 DOI: 10.1016/j.xcrm.2022.100623
Source DB: PubMed Journal: Cell Rep Med ISSN: 2666-3791